Differential Enzyme-Immunoassay for HIV-1 Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current HIV detection assays struggle to differentiate between vaccine-generated antibodies and those produced after true HIV infection, leading to false positives and exclusion of vaccine trial participants from blood donation and other opportunities, and there is a need for a method that can accurately detect HIV-1 infection in the presence of vaccine-induced antibodies.
Innovation Solution
The use of novel HIV-1 epitopes identified through gene-fragment phage display libraries, specifically the HIV-1 GAG p6 and gp41 epitopes, to construct differential enzyme-immunoassays that distinguish between infection-induced and vaccine-induced anti-HIV reactivities, allowing for the detection of anti-HIV-1 antibodies in biological samples.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If licensed HIV serodetection assays are used to detect HIV infection, then sensitivity for detecting true HIV infection is improved, but specificity deteriorates due to cross-reactivity with vaccine-generated antibodies
Solution Approach 1:
The patent segments the HIV detection process into two distinct stages: initial screening using licensed assays to capture all potential positives (including vaccine reactors), and subsequent differentiation using peptide arrays with conserved epitopes to distinguish true infections from vaccine-induced reactivity. This segmentation resolves the contradiction by allowing each stage to optimize for its specific function.
Solution Approach 2:
The patent introduces peptide arrays containing conserved HIV epitopes as an intermediary tool between the initial screening and final diagnosis. These peptides act as mediators that bind specifically to infection-induced antibodies but not to vaccine-generated antibodies, enabling differentiation without compromising the sensitivity of the initial screen.
2Reliability
If complex HIV vaccine products containing multiple viral genes or proteins are used, then immunogenicity is improved, but differentiation between vaccine-induced and infection-induced antibodies becomes more difficult
Solution Approach 1:
The patent applies local quality by focusing on specific conserved epitopic regions within the complex HIV proteins used in vaccines. Rather than attempting to differentiate based on the entire complex vaccine product, the method identifies and targets specific local regions (conserved epitopes) that maintain their immunogenicity properties while being distinguishable markers for true infection.
Solution Approach 2:
The patent creates a universal differentiation method using conserved epitopes that function across multiple vaccine platforms. The same peptide array approach can differentiate infection-induced antibodies regardless of which complex vaccine product was administered, making the solution universally applicable to various HIV vaccine candidates.
3Adaptability or versatility
If multiple peptides are used to detect HIV infection, then coverage of HIV variants is improved, but assay complexity increases
Solution Approach 1:
The patent merges multiple peptide detection capabilities into a single integrated peptide array platform. Rather than running separate assays for different HIV variants, the method combines multiple conserved epitope peptides on one array, allowing simultaneous detection of antibodies against various HIV variants in a single test.
Solution Approach 2:
The patent transitions from sequential or parallel separate peptide assays to a two-dimensional peptide array format. This dimensional change allows multiple peptides to be tested simultaneously in a single well, reducing assay complexity while maintaining comprehensive variant coverage.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method effectively differentiates between vaccine-induced and infection-induced antibodies, enabling early detection of HIV-1 infections and reducing false positives, thus facilitating the recruitment of participants into HIV vaccine trials and ensuring accurate identification of infected individuals.
Implementation Method 1
contacting said biological sample with an epitope set comprising epitopes that are recognized by said anti-HIV-1 antibody, wherein said epitope set consists essentially of an HIV-1 GAG p6 epitope or epitopes, an HIV-1/vpu epitope or epitopes and an HIV-1 gp41 terminal region epitope or epitopes, said contacting being under conditions sufficient to permit said anti-HIV-1 antibody if present in said sample to bind to epitopes in said epitope set and form an epitope-anti-HIV-1 antibody complex
Implementation Method 2
contacting said formed epitope-anti-HIV-1 antibody complex with an anti-HIV-1 antibody binding molecule, said contacting being under conditions sufficient to permit said anti-HIV-1 antibody binding molecule to bind to anti-HIV-1 antibody of said formed epitope-anti-HIV-1 antibody complex and form an extended complex
Data Source
Figure 1
Figure 2
Figure 3
AI summary
This invention relates to compositions and methods for the detection of immunodeficiency virus infection, especially immunodeficiency virus- 1 (HIV-I) infection. The invention particularly concerns compositions and methods that may be used in HIV vaccine recipients whose sera may contain vaccine-generated anti-HIV-1 antibodies.